Bausch Health Companies Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bausch Health Companies Inc. on June 26, 2026. The report discloses a material corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Board Departure: Mr. Michael Goettler notified the Company of his resignation from the Board of Directors, effective June 30, 2026.
- Reason for Departure: The resignation is in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC.
- Nature of Departure: The resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or new risk factors. A press release dated July 1, 2026, announcing the resignation is furnished as Exhibit 99.1 but is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the effective date of Mr. Goettler's resignation (June 30, 2026).
- Confirm the new role and employer of the departing director (President and CEO of Knoa Pharma LLC).
- Review the Company's subsequent filings to determine if a replacement director has been nominated or elected.
- Check for any related press releases or disclosures regarding the transition of board responsibilities.